2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Gastrointestinal
4
Conditions
Carcinoma, Non-Small-Cell Lung
47
Carcinoma, Hepatocellular
29
Neoplasms
18
Neoplasm Metastasis
14
Melanoma
14
Stomach Neoplasms
13
Esophageal Neoplasms
13
Colorectal Neoplasms
12
Nasopharyngeal Carcinoma
10
Esophageal Squamous Cell Carcinoma
10
Triple Negative Breast Neoplasms
9
Head and Neck Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Breast Neoplasms
8
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Lung Neoplasms
7
Carcinoma, Renal Cell
7
Biliary Tract Neoplasms
7
Small Cell Lung Carcinoma
6
Colonic Neoplasms
5
Cholangiocarcinoma
5
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Liver Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Interventions
Sorafenib
68
Bevacizumab
44
Oxaliplatin
25
Doxorubicin
22
Gemcitabine
21
Fluorouracil
21
Radiosurgery
20
Nivolumab
19
durvalumab
18
Radiofrequency Ablation
18
pembrolizumab
17
lenvatinib
17
Cisplatin
17
Capecitabine
17
atezolizumab
14
Leucovorin
14
Hepatectomy
14
Radiotherapy
12
tremelimumab
10
Irinotecan
10
Drug Therapy
10
Cyclophosphamide
10
Carboplatin
10
Blood Specimen Collection
10
Ipilimumab
9
regorafenib
8
Liver Transplantation
8
Everolimus
8
Cryosurgery
8
Chemotherapy, Adjuvant
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05713994
2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
300 enrolled
NCT05497453
2025-02-03
MYCHELANGELO I
Omega Therapeutics
Phase 1/2
Terminated
24 enrolled
NCT03817736
2024-05-09
START-FIT
The University of Hong Kong
Phase 2
Completed
33 enrolled
NCT05322187
2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3
Unknown
15 enrolled